Real-word evidence on healthcare resource use and associated costs in on-demand users of replacement therapies in von Willebrand disease in France: the FORvWARD study.

Key Points

• The study aims to analyze healthcare resource use and costs associated with replacement therapies in on-demand users of von Willebrand disease treatments.
• Used the French healthcare claims database to identify adult patients with VWD receiving replacement therapy.
• Analyzed treatment patterns, healthcare resource utilization, and associated costs over defined exposure periods starting from the first treatment dispensation.
• Employed Generalized Estimating Equation models to account for confounding factors across different treatments.
• WILFACTIN® was the most commonly used replacement therapy, with mean total RT dose of 12,962 IU and mean cost of €21,034 per exposure period.
• WILFACTIN®-treated patients had longer hospital stays and higher costs compared to VEYVONDI®-treated patients.
• VEYVONDI® appears to be a more cost-saving option relative to other replacement therapies.